Restatement of previously reported information |
|
|
October 31, 2015 |
|
|
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
Selected Consolidated Balance Sheet Accounts |
|
|
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other current assets |
|
$ |
74,757 |
|
|
$ |
335,878 |
|
|
$ |
410,635 |
|
Total current assets |
|
$ |
2,512,187 |
|
|
$ |
335,878 |
|
|
$ |
2,848,065 |
|
Total assets |
|
$ |
7,641,661 |
|
|
$ |
335,878 |
|
|
$ |
7,977,539 |
|
Additional paid in capital |
|
$ |
87,685,381 |
|
|
$ |
914,270 |
|
|
$ |
88,599,651 |
|
Accumulated deficit |
|
$ |
(81,200,061 |
) |
|
$ |
(578,392 |
) |
|
$ |
(81,778,453 |
) |
Total stockholders' equity |
|
$ |
6,561,656 |
|
|
$ |
335,878 |
|
|
$ |
6,897,534 |
|
Total liabilities and stockholders' equity |
|
$ |
7,641,661 |
|
|
$ |
335,878 |
|
|
$ |
7,977,539 |
|
|
|
Three Months Ended
October 31, 2 015 |
|
|
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
Consolidated Statement of Operations |
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
439,711 |
|
|
|
|
|
|
|
439,711 |
|
Compensation expense |
|
|
400,507 |
|
|
|
|
|
|
|
400,507 |
|
Director fee |
|
|
9,000 |
|
|
|
|
|
|
|
9,000 |
|
Legal and professional |
|
|
57,988 |
|
|
|
|
|
|
|
57,988 |
|
General and administrative |
|
|
222,039 |
|
|
|
506,573 |
|
|
|
728,612 |
|
Loss from operations |
|
|
(1,129,245 |
) |
|
|
(506,573 |
) |
|
|
(1,635,818 |
) |
Unrealized gain on change in derivative |
|
|
29,746 |
|
|
|
(29,746 |
) |
|
|
|
|
Other expenses |
|
|
430 |
|
|
|
|
|
|
|
430 |
|
Interest expense, net |
|
|
(194 |
) |
|
|
|
|
|
|
(194 |
) |
Total other income (expense),
net |
|
|
29,982 |
|
|
|
(29,746 |
) |
|
|
236 |
|
Net loss |
|
$ |
(1,099,263 |
) |
|
$ |
(536,319 |
) |
|
$ |
(1,635,582 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
$ |
0.00 |
|
|
$ |
|
|
|
$ |
0.00 |
|
|
|
Six Months Ended
October 31, 2015 |
|
|
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
Consolidated Statement of Operations |
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development costs |
|
|
595,389 |
|
|
|
|
|
|
|
595,389 |
|
Compensation expense |
|
|
848,077 |
|
|
|
|
|
|
|
848,077 |
|
Director fee |
|
|
27,000 |
|
|
|
|
|
|
|
27,000 |
|
Legal and professional |
|
|
183,063 |
|
|
|
|
|
|
|
183,063 |
|
General and administrative |
|
|
483,454 |
|
|
|
1,013,146 |
|
|
|
1,496,600 |
|
Loss from operations |
|
|
(2,136,983 |
) |
|
|
(1,013,146 |
) |
|
|
(3,150,129 |
) |
Unrealized gain on change in derivative |
|
|
492,049 |
|
|
|
(492,049 |
) |
|
|
|
|
Other expenses |
|
|
335 |
|
|
|
|
|
|
|
335 |
|
Interest expense, net |
|
|
(826 |
) |
|
|
|
|
|
|
(826 |
) |
Total other income (expense),
net |
|
|
491,558 |
|
|
|
(492,049 |
) |
|
|
(491 |
) |
Net loss |
|
$ |
(1,645,425 |
) |
|
$ |
(1,505,195 |
) |
|
$ |
(3,150,620 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
|
$ |
0.00 |
|
|
$ |
|
|
|
$ |
0.00 |
|
|
|
Three Months Ended
October 31, 2015 |
|
|
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
Consolidated Statement of Comprehensive Loss |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(1,099,263 |
) |
|
$ |
(536,319 |
) |
|
$ |
(1,635,582 |
) |
Foreign currency translation adjustment |
|
|
(34 |
) |
|
|
|
|
|
|
(34 |
) |
Comprehensive loss |
|
$ |
(1,099,297 |
) |
|
$ |
(536,319 |
) |
|
$ |
(1,635,616 |
) |
|
|
Six Months Ended
October 31, 2015 |
|
|
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
Consolidated Statement of Comprehensive Loss |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(1,645,425 |
) |
|
$ |
(1,505,195 |
) |
|
$ |
(3,150,620 |
) |
Foreign currency translation adjustment |
|
|
1,587 |
|
|
|
|
|
|
|
1,587 |
|
Comprehensive loss |
|
$ |
(1,643,838 |
) |
|
$ |
(1,505,195 |
) |
|
$ |
(3,149,033 |
) |
|
|
Six Months Ended
October 31, 2015 |
|
|
|
As
Previously Reported |
|
|
Adjustment |
|
|
As
Restated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Statement of Cash Flows |
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(1,645,425 |
) |
|
$ |
(1,505,195 |
) |
|
$ |
(3,150,620 |
) |
Stock issued for services |
|
|
|
|
|
|
333,216 |
|
|
|
333,216 |
|
Stock issued for compensation |
|
|
254,040 |
|
|
|
|
|
|
|
254,040 |
|
Stock based compensation - options |
|
|
287,928 |
|
|
|
|
|
|
|
287,928 |
|
Stock based compensation - warrants |
|
|
|
|
|
|
679,930 |
|
|
|
679,930 |
|
Gain on derivative liability |
|
|
(492,049 |
) |
|
|
492,049 |
|
|
|
|
|
Increase in prepaid expenses and current assets |
|
|
(80,500 |
) |
|
|
|
|
|
|
(80,500 |
) |
Decrease in accounts payable |
|
|
(69,491 |
) |
|
|
|
|
|
|
(69,491 |
) |
Increase in accrued expenses |
|
|
29,130 |
|
|
|
|
|
|
|
29,130 |
|
Decrease in license agreement
obligation |
|
|
(400,000 |
) |
|
|
|
|
|
|
(400,000 |
) |
Net cash used in operating
activities |
|
|
(2,116,367 |
) |
|
|
|
|
|
|
(2,116,367 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Net cash from investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from sale of common
stock |
|
|
1,728,935 |
|
|
|
|
|
|
|
1,728,935 |
|
Net cash provided by financing
activities |
|
|
1,728,935 |
|
|
|
|
|
|
|
1,728,935 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of currency rate exchange on cash |
|
|
125 |
|
|
|
|
|
|
|
125 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net decrease in cash |
|
|
(387,307 |
) |
|
|
|
|
|
|
(387,307 |
) |
Cash at beginning of year |
|
|
2,699,737 |
|
|
|
|
|
|
|
2,699,737 |
|
Cash at October 31, 2015 |
|
$ |
2,312,430 |
|
|
$ |
|
|
|
$ |
2,312,430 |
|
|